Scott A. Yerby Sells 648 Shares of SI-Bone Inc (NASDAQ:SIBN) Stock

SI-Bone Inc (NASDAQ:SIBN) insider Scott A. Yerby sold 648 shares of the business’s stock in a transaction on Monday, July 8th. The stock was sold at an average price of $19.01, for a total value of $12,318.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Shares of SIBN stock opened at $19.80 on Friday. SI-Bone Inc has a 1-year low of $14.08 and a 1-year high of $23.03. The stock’s fifty day simple moving average is $17.91. The company has a current ratio of 13.06, a quick ratio of 12.70 and a debt-to-equity ratio of 0.47.

SI-Bone (NASDAQ:SIBN) last announced its earnings results on Wednesday, May 8th. The company reported ($0.38) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.13). The company had revenue of $14.99 million during the quarter. On average, equities research analysts forecast that SI-Bone Inc will post -1.45 earnings per share for the current fiscal year.

A number of hedge funds have recently made changes to their positions in SIBN. Orbimed Advisors LLC purchased a new position in SI-Bone during the 4th quarter worth $20,584,000. RTW Investments LP purchased a new position in SI-Bone during the 4th quarter worth $16,802,000. BlackRock Inc. purchased a new position in SI-Bone during the 4th quarter worth $15,835,000. Pura Vida Investments LLC purchased a new position in SI-Bone during the 4th quarter worth $4,485,000. Finally, Federated Investors Inc. PA grew its stake in SI-Bone by 111.4% during the 1st quarter. Federated Investors Inc. PA now owns 370,000 shares of the company’s stock worth $6,971,000 after buying an additional 195,000 shares during the last quarter. Hedge funds and other institutional investors own 38.89% of the company’s stock.

Several research analysts have recently commented on the company. ValuEngine lowered Zosano Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, May 1st. Zacks Investment Research lowered Yatra Online from a “hold” rating to a “sell” rating in a research report on Saturday, July 6th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. SI-Bone presently has an average rating of “Buy” and a consensus price target of $24.75.

SI-Bone Company Profile

SI-BONE, Inc, a medical device company, develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. It offers iFuse, an implant system to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. The company was founded in 2008 and is headquartered in Santa Clara, California.

Recommended Story: What is the S&P 500 Index?

Insider Buying and Selling by Quarter for SI-Bone (NASDAQ:SIBN)

Receive News & Ratings for SI-Bone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SI-Bone and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit